The combination of the PARP1 inhibitor talazoparib with etoposide/carboplatin produced highly mixed results with a subset of SCLC lines having enhanced cytotoxicity with the combination and another subset having decreased cytotoxicity with the combination (Fig. 6D). This evidence concerns the gene PARP1 and small cell lung carcinoma.